Eli Lilly & Co. (LLY)

122.48
1.73 1.43
NYSE : Health Technology
Prev Close 120.75
Open 121.18
Day Low/High 120.40 / 122.48
52 Wk Low/High 74.51 / 121.84
Volume 10.13M
Avg Volume 4.92M
Exchange NYSE
Shares Outstanding 1.06B
Market Cap 126.75B
P/E Ratio 38.23
Div & Yield 2.58 (1.88%)
Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.

Eli Lilly Has a Dominant Trend: Down

Eli Lilly Has a Dominant Trend: Down

A chart buyer will actually wait for the trend to turn before buying.

Eli Lilly numbers reduced at Leerink

Scanning the Earnings Universe, Plus Overnight Tidbits

Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...

Pivotal Research Is Not Chickening Out

Pivotal Research Is Not Chickening Out

A class-action lawsuit over poultry pricing could result in substantial damages for Tyson Foods, analyst says.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Eli Lilly upgraded at Goldman

Eli Lilly Can't Put the Petal to the Metal

Eli Lilly Can't Put the Petal to the Metal

The stock appears to have lost its way.

An Options Play in Eli Lilly

An Options Play in Eli Lilly

I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

I like a bearishly biased, slightly-out-of-the-money vertical put spread.

Eli Lilly upgraded at JP Morgan

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Intermediate Level Trade: Eli Lilly

Intermediate Level Trade: Eli Lilly

Consider that the $70 line of support.

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.

Are We Sitting Atop Another 8-Year Peak?

Are We Sitting Atop Another 8-Year Peak?

The market action looks very much like it did before the drops that occurred in 2000 and 2008.

Here Is Jim Cramer's Take on Eli Lilly Shares

Here Is Jim Cramer's Take on Eli Lilly Shares

Jim Cramer says Eli Lilly has been overpromising and underdelivering.

Why I Feel Bearish About the Market

Why I Feel Bearish About the Market

I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.

Watch the $78 Level on Eli Lilly

Watch the $78 Level on Eli Lilly

If buyers don't appear around $78 then a deeper correction is likely.

Trending Tickers: ORCL, N, FB, BA, LLY

Trending Tickers: ORCL, N, FB, BA, LLY

Facebook continued to reap the rewards of its strong quarterly results today.

Eli Lilly numbers raised at BMO

Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

U.S. stocks retreat into the red as a number of positive and negative earnings reports keep trading choppy.

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Lilly's Charts Don't Prescribe an Outright Buy

Our quantitative service has upgraded the drug maker to a buy, but the technicals are not ready yet to join in.

LLY Investor Mtg.

2 Promising Biopharmas Reach Key Junctures

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

BofA/Merrill Healthcare Conf.